Abstract
1348P - Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: Results from two phase II studies
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have